The Direct Benefit of Neuropsychological Assessment with Feedback in Multiple Sclerosis

Not Applicable

• Conditions: Multiple Sclerosis; Psychological health of caregivers; Neurological - Multiple sclerosis; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12612000161820
• Lead Sponsor: Wendy Longley

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-02-06
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

MS diagnosed by a neurologist
Referral for a non-urgent neuropsychological assessment.
Patients do not have to have a caregiver to participate.

Exclusion Criteria

* History of a developmental intellectual disability
* Severe cognitive impairment, including suspected MS-related dementia
* Significantly impaired hearing despite use of prescribed hearing aids or other equipment
* Impaired command of English due to non-English speaking background or aphasia
* Severe dysarthria or significantly impaired voice volume
* Current severe psychiatric impairment (e.g. severe depression, anxiety, or psychosis)
* Impaired ability to manage the practical requirements of the study, such as an unstable medical or health condition causing delirium or hospitalizations, or a lack of reliable access to a telephone and mailbox due to unstable accommodation and/or support arrangements

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary Outcome 2: Improved patient use of adaptive psychological strategies for coping with the health problems caused by MS on the Coping with Health and Illness Problems scale.[Week 1 for the wait-list control group, <br>Week 5, 9, 13 for both groups, and <br>Week 17 for the intervention group];Primary Outcome 3: Improved caregiving outcomes for the caregiver on the Bakas Caregiving Outcomes Scale[Week 1 for the wait-list control group, <br>Week 5, 9, 13 for both groups, and <br>Week 17 for the intervention group];Primary Outcome 1: Improved patient and/or caregiver knowledge of the patient's specific cognitive strengths and weaknesses on the Multiple Sclerosis Neuropsychological Questionnaire and the Domains of Cognitive Impairment Check-list[Week 1 for the wait-list control group, <br>Week 5, 9, 13 for both groups, and <br>Week 17 for the intervention group]